ABBV241227C175000
- 3.05
- 0.000.00%
AbbVie Newsroom
SpringWorks Therapeutics Jumps Amid Takeover Speculation
Redburn Atlantic Adjusts Price Target on AbbVie to $214 From $216, Keeps Buy Rating
AbbVie Unusual Options Activity For January 10
AbbVie to Book $3.5 Billion Impairment Charge Related to Potential Antipsychotic Drug Emraclidine
AbbVie Estimates Non-Cash After-Tax Intangible Asset-Impairment Charge of About $3.5B >ABBV
Express News | Abbvie Inc - to Monitor Remaining Intangible Assets of $3.6 Billion
Express News | Abbvie Inc - to Record Impairment Charge for Emraclidine Asset
Express News | Alector Inc: On Jan 9, Abbvie Provided Written Notice to Company Terminating Trem2 Program
Pharma Companies Welcome New Year With 583 Drug Price Hikes so Far
Express News | Light Horse: Financing Led by Versant Ventures and Included Mubadala Capital, Bristol-Myers, Taiho Ventures, and Abbvie
Express News | Light Horse Therapeutics Debuts With $62 Mln Series a Financing
Novo, Eli Lilly to Dominate Global Pharma Sales in 2025: Report
AbbVie's Strategic Acquisition and Long-Term Growth Potential Justify Buy Rating Despite Short-Term EPS Adjustments
AbbVie to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Assessing AbbVie: Insights From 17 Financial Analysts
8 Health Care Stocks Whale Activity In Today's Session
Resilience Partners With Parvus Therapeutics for Development and Manufacturing of PVT401, a Novel Autoimmune Drug Candidate for IBD
AbbVie Price Target Cut to $211.00/Share From $215.00 by Truist Securities
AbbVie Is Maintained at Buy by Truist Securities
AbbVie Analyst Ratings